Search NASA⌕ Search

Engineering topics

Rojas, Camilo

Publications and source records attributed to Rojas, Camilo.

Exclusive $|V_{ub}|$ determinations using Padé Approximants

We determine the CKM parameter |V ub | from the exclusive semileptonic decays B→πℓν ℓ and B s →Kℓν ℓ , employing Lattice QCD theoretical information on the form factors in combination with experimental measurements of the differential branching ratio distributions. Using Pad\'{e} approximants to the participating form factors we obtain |V ub |=3.86(11)x10 -3 and |V ub |=3.58(9)x10 -3 from the analyses of the individual decay channels, respectively, and |V ub |=3.68(5)x10 -3 from a simultaneous analysis of both decays. Our results highlight the importance of the decay B s →Kμν μ in complementing the traditional B→πℓν ℓ one in the exclusive determination of |V ub | , and strengthens the case for precise measurements of the differential B s →Kℓν ℓ decay rate with a finer resolution of the q 2 bins, as it would definitely allow achieving more conclusive results for |V ub | .

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors

Highlights: •Ebselen, chelerythrine and apomorphine were identified as glutaminase inhibitors. •These had greater affinities and efficiency of inhibition than known prototypes. •Their previously reported biological activity could be due to glutaminase inhibition. -- Abstract: Glutaminase catalyzes the hydrolysis of glutamine to glutamate and plays a central role in the proliferation of neoplastic cells via glutaminolysis, as well as in the generation of excitotoxic glutamate in central nervous system disorders such as HIV-associated dementia (HAD) and multiple sclerosis. Both glutaminase siRNA and glutaminase inhibition have been shown to be effective in in vitro models of cancer and HAD, suggesting a potential role for small molecule glutaminase inhibitors. However, there are no potent, selective inhibitors of glutaminase currently available. The two prototypical glutaminase inhibitors, BPTES and DON, are either insoluble or non-specific. In a search for more drug-like glutaminase inhibitors, we conducted a screen of 1280 in vivo active drugs (Library of Pharmacologically Active Compounds (LOPAC{sup 1280})) and identified ebselen, chelerythrine and (R)-apomorphine. The newly identified inhibitors exhibited 10 to 1500-fold greater affinities than DON and BPTES and over 100-fold increased efficiency of inhibition. Although non-selective, it is noteworthy that the affinity of ebselen for glutaminase is more potent than any other activity yet described. It is possible that the previously reported biological activity seen with these compounds is due, in part, to glutaminase inhibition. Ebselen, chelerythrine and apomorphine complement the armamentarium of compounds to explore the role of glutaminase in disease.

60 APPLIED LIFE SCIENCES↗